Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Rallybio Yönetim

Yönetim kriter kontrolleri 2/4

Rallybio's CEO'su Steve Uden, Jan2018 tarihinde atandı, in görev süresi 6.75 yıldır. in toplam yıllık tazminatı $ 1.78M olup, şirket hissesi ve opsiyonları dahil olmak üzere 29.8% maaş ve 70.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.73% ine doğrudan sahiptir ve bu hisseler $ 841.38K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.8 yıl ve 4.1 yıldır.

Anahtar bilgiler

Steve Uden

İcra Kurulu Başkanı

US$1.8m

Toplam tazminat

CEO maaş yüzdesi	29.8%
CEO görev süresi	6.8yrs
CEO sahipliği	1.7%
Yönetim ortalama görev süresi	5.8yrs
Yönetim Kurulu ortalama görev süresi	4.1yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

May 15

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Jan 30

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Oct 31

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Jul 07

Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

Mar 16

CEO Tazminat Analizi

Steve Uden'un ücretlendirmesi Rallybio'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$74m
Mar 31 2024	n/a	n/a	-US$76m
Dec 31 2023	US$2m	US$530k	-US$75m
Sep 30 2023	n/a	n/a	-US$71m
Jun 30 2023	n/a	n/a	-US$71m
Mar 31 2023	n/a	n/a	-US$69m
Dec 31 2022	US$1m	US$491k	-US$67m
Sep 30 2022	n/a	n/a	-US$63m
Jun 30 2022	n/a	n/a	-US$55m
Mar 31 2022	n/a	n/a	-US$48m
Dec 31 2021	US$3m	US$441k	-US$47m
Sep 30 2021	n/a	n/a	-US$45m
Jun 30 2021	n/a	n/a	-US$42m
Mar 31 2021	n/a	n/a	-US$36m
Dec 31 2020	US$838k	US$380k	-US$26m

Tazminat ve Piyasa: Steve 'nin toplam tazminatı ($USD 1.78M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 677.23K ).

Tazminat ve Kazançlar: Steve şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Steve Uden (66 yo)

6.8yrs

Görev süresi

US$1,778,284

Tazminat

Dr. Stephen Uden, also known as Steve, MD, is Chief Executive Officer and Director of Rallybio, LLC since August 01, 2023 and serves as its President. Dr. Uden is a Co-Founder of Rallybio, LLC in 2018 and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Martin MacKay	Co-Founder & Executive Chairman	6.8yrs	US$1.78m	1.73% $ 791.0k
Stephen Uden	Co-Founder	6.8yrs	US$1.78m	1.73% $ 791.0k
Jonathan Lieber	CFO & Treasurer	1.7yrs	US$1.91m	0.012% $ 5.5k
Steven Ryder	Chief Medical Officer	5.8yrs	US$1.27m	0.46% $ 211.6k

5.8yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim: RLYB 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Martin MacKay	Co-Founder & Executive Chairman	6.8yrs	US$1.78m	1.73% $ 791.0k
Stephen Uden	Co-Founder	1.2yrs	US$1.78m	1.73% $ 791.0k
Ronald Hunt	Independent Director	6.8yrs	US$115.45k	0% $ 0
Robert Hopfner	Independent Director	4.6yrs	US$115.45k	0% $ 0
Christine Nash	Independent Director	2.5yrs	US$108.95k	0% $ 0
Kush Parmar	Independent Director	6.5yrs	US$111.95k	0% $ 0
Helen Boudreau	Independent Director	4.1yrs	US$118.95k	0.058% $ 26.3k
Lucian Iancovici	Independent Director	4.4yrs	Veri yok	Veri yok
Paula Soteropoulos	Independent Director	4yrs	US$113.95k	0.058% $ 26.3k
Wendy Chung	Independent Director	2.2yrs	US$95.00k	0% $ 0
Hui Liu	Independent Director	2.5yrs	US$111.45k	0% $ 0

4.1yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RLYB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.1 yıldır).

Rallybio Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Rallybio Corporation, Annual General Meeting, May 15, 2024

Rallybio Corporation Announces Executive Changes

Rallybio Corporation Announces Chief Financial Officer Changes

High number of new directors

Rallybio Corporation Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors

Rallybio Corporation Announces Retirement of Jeffrey Fryer as Chief Financial Officer

Recent updates

Rallybio Announces Publication of RLYB212 Phase 1 Proof-Of-Concept Study Results in Thrombosis and Haemostasis

We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully

Price target decreased by 19% to US$10.50

Rallybio Corporation(NasdaqGS:RLYB) dropped from Russell 3000 Index

Rallybio Corporation Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Rlybocytopenia

Ralebio Corporation Announces the Presentation of Results from FNAIT Systematic Literature Review and Meta- Analysis At the Academy of Managed Care Pharmacy 2024 Annual Meeting

Rallybio Corporation, Annual General Meeting, May 15, 2024

Rallybio Corporation announced that it has received $6.599999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Price target decreased by 32% to US$9.38

Rallybio Corporation Announces the Prioritization of Its Portfolio and a 45% Workforce Reduction to Focus Resources on Its Phase 2-Ready Clinical Stage Programs

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Rallybio Corporation Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116

Rallybio Corporation Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212

New major risk - Share price stability

New minor risk - Market cap size

Rallybio Corporation Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

Rallybio Corporation Presents Phase 1 Single Ascending Dose Data for RLYB116, Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Price target decreased by 7.3% to US$16.83

Rallybio Corporation Announces Executive Changes

Rallybio Corporation Reports Data from the Phase 1b Proof-Of-Concept Study of RLYB212

Price target decreased by 9.9% to US$18.17

Rallybio to Present Data from the RLYB212 Phase 1b Proof-Of-Concept Study

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Price target decreased by 7.2% to US$22.50

Rallybio Corporation Announces Chief Financial Officer Changes

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Rallybio Announces Publication of Data Highlighting the Ability of HPA-1A-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT

Price target decreased to US$28.00

High number of new directors

Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Price target increased to US$30.67

Rallybio Corporation Expects to Discuss the Preliminary Platelet Elimination Data by the End of the Third Quarter of 2022

Rallybio Corporation Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Rallybio Corporation Announces Retirement of Jeffrey Fryer as Chief Financial Officer

High number of new directors

Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi

High number of new directors

Rallybio Corporation, Annual General Meeting, May 24, 2022

High number of new directors

Rallybio Corporation Announces Board Changes

Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

CEO & Chairman recently bought US$103k worth of stock

High number of new directors

Rallybio Corporation Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş